As for the hub RPS4X, it has been proven that dysregulation of RP expression occurs in a variety of human diseases, notably in many cancers (O’Leary et al. 2016), and altered expression of some RPs correlates with different tumor phenotypes and patient survival (Dolezal et al. 2018), including the prostatic one. This evidence concerns the gene RPS4X and neoplasm.